Asia Renal Care Limited, headquartered in Singapore (SG), is a leading provider in the renal care industry, specialising in dialysis services and related healthcare solutions. Founded in 2005, the company has established a strong presence across Asia, with operations in several key regions, including Malaysia and Indonesia. Asia Renal Care Limited is dedicated to delivering high-quality, patient-centred care through its state-of-the-art dialysis facilities and innovative treatment options. The company’s commitment to excellence is reflected in its advanced technology and skilled healthcare professionals, setting it apart in a competitive market. With a focus on improving patient outcomes, Asia Renal Care Limited has achieved significant milestones, positioning itself as a trusted name in renal healthcare. Its reputation for reliability and quality service continues to drive its growth and expansion across the region.
How does Asia Renal Care Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Asia Renal Care Limited's score of 36 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Asia Renal Care Limited, headquartered in Singapore (SG), currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Fresenius Medical Care AG, which influences its climate commitments and emissions reporting. As part of its corporate family relationship, Asia Renal Care Limited inherits climate initiatives and targets from Fresenius Medical Care AG. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions across their operations. While specific reduction targets or achievements for Asia Renal Care Limited are not detailed, the overarching goals set by Fresenius Medical Care AG guide the company's climate strategy. These initiatives reflect a commitment to sustainability and reducing environmental impact within the healthcare sector. In summary, while Asia Renal Care Limited does not provide specific emissions data or reduction targets, it aligns with the climate commitments of its parent company, Fresenius Medical Care AG, to foster a more sustainable future.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000.0 |
| Scope 2 | 557,200,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000.0 |
Asia Renal Care Limited's Scope 3 emissions, which decreased by 100% last year and decreased by approximately 100% since 2023, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Purchased Goods and Services" being the largest emissions source at 17640922% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Asia Renal Care Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.